254 related articles for article (PubMed ID: 16230258)
1. Key issues in end point selection for heart failure trials: composite end points.
Neaton JD; Gray G; Zuckerman BD; Konstam MA
J Card Fail; 2005 Oct; 11(8):567-75. PubMed ID: 16230258
[TBL] [Abstract][Full Text] [Related]
2. A global ranking approach to end points in trials of mechanical circulatory support devices.
Felker GM; Anstrom KJ; Rogers JG
J Card Fail; 2008 Jun; 14(5):368-72. PubMed ID: 18514927
[TBL] [Abstract][Full Text] [Related]
3. Determining the most appropriate components for a composite clinical trial outcome.
Bethel MA; Holman R; Haffner SM; Califf RM; Huntsman-Labed A; Hua TA; McMurray J
Am Heart J; 2008 Oct; 156(4):633-40. PubMed ID: 18926145
[TBL] [Abstract][Full Text] [Related]
4. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
Le Tourneau C; Michiels S; Gan HK; Siu LL
J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
[TBL] [Abstract][Full Text] [Related]
5. Measurement of end points in heart failure trials: jousting at windmills?
Hauptman PJ
Mt Sinai J Med; 2004 Oct; 71(5):298-304. PubMed ID: 15543430
[TBL] [Abstract][Full Text] [Related]
6. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention.
Kip KE; Hollabaugh K; Marroquin OC; Williams DO
J Am Coll Cardiol; 2008 Feb; 51(7):701-7. PubMed ID: 18279733
[TBL] [Abstract][Full Text] [Related]
7. Designs for mechanical circulatory support device studies.
Neaton JD; Normand SL; Gelijns A; Starling RC; Mann DL; Konstam MA
J Card Fail; 2007 Feb; 13(1):63-74. PubMed ID: 17339005
[TBL] [Abstract][Full Text] [Related]
8. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
Powers JH
Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of the results of clinical trials: surrogate end points and composite end points.
Gensini GF; Conti AA
Minerva Med; 2004 Feb; 95(1):71-5. PubMed ID: 15041928
[TBL] [Abstract][Full Text] [Related]
10. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
[TBL] [Abstract][Full Text] [Related]
11. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
12. Some issues with composite endpoints in clinical trials.
Chi GY
Fundam Clin Pharmacol; 2005 Dec; 19(6):609-19. PubMed ID: 16313272
[TBL] [Abstract][Full Text] [Related]
13. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
[TBL] [Abstract][Full Text] [Related]
14. Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
Cohn J; Cleland JG; Lubsen J; Borer JS; Steg PG; Perelman M; Zannad F
J Card Fail; 2009 Apr; 15(3):199-205. PubMed ID: 19327621
[TBL] [Abstract][Full Text] [Related]
15. Composite outcomes in randomized clinical trials: arguments for and against.
Ross S
Am J Obstet Gynecol; 2007 Feb; 196(2):119.e1-6. PubMed ID: 17306647
[TBL] [Abstract][Full Text] [Related]
16. TEACH: Trial of Education And Compliance in Heart dysfunction chronic disease and heart failure (HF) as an increasing problem.
Gwadry-Sridhar F; Guyatt G; O'Brien B; Arnold JM; Walter S; Vingilis E; MacKeigan L
Contemp Clin Trials; 2008 Nov; 29(6):905-18. PubMed ID: 18703166
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
Linde C; Gold M; Abraham WT; Daubert JC;
Am Heart J; 2006 Feb; 151(2):288-94. PubMed ID: 16442890
[TBL] [Abstract][Full Text] [Related]
18. Surrogate end points in clinical research: hazardous to your health.
Grimes DA; Schulz KF
Obstet Gynecol; 2005 May; 105(5 Pt 1):1114-8. PubMed ID: 15863552
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of quantitative baseline ST-segment elevation for predicting outcomes after primary coronary angioplasty or fibrinolysis (results from the DANAMI-2 trial).
Sejersten M; Ripa RS; Maynard C; Wagner GS; Andersen HR; Grande P; Mortensen LS; Clemmensen P
Am J Cardiol; 2006 Mar; 97(5):611-6. PubMed ID: 16490423
[TBL] [Abstract][Full Text] [Related]
20. A study design to assess the safety and efficacy of on-pump versus off-pump coronary bypass grafting: the ROOBY trial.
Novitzky D; Shroyer AL; Collins JF; McDonald GO; Lucke J; Hattler B; Kozora E; Bradham DD; Baltz J; Grover FL;
Clin Trials; 2007; 4(1):81-91. PubMed ID: 17327248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
